Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables

  Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of
                             Generic Injectables

Unilife to receive $40MM in upfront and milestone payments

15-year supply agreement to launch initial 20 generic injectable drugs in
syringes from Unifill platform

Unilife to begin commercial supply in FY 2014, annual minimum unit volume to
exceed 175MM

PR Newswire

YORK, Pa., Nov. 20, 2013

YORK, Pa., Nov. 20, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife")
(NASDAQ: UNIS, ASX: UNS) today announced the signing of a long-term commercial
supply contract with Hikma Pharmaceuticals  PLC ("Hikma") (LSE: HIK) for the
use of Unifill^® prefilled syringes with a range of generic injectable drugs.

Under the 15-year global agreement, Unilife will supply Hikma with customized
prefillable delivery systems from its Unifill^® platform, including the
Unifill syringe and the Unifill Nexus^™ ("Unifill products").

Hikma has selected an initial list of 20 of its generic injectable products to
be used with Unifill products. Unilife has granted Hikma exclusive global
rights to its Unifill products for use with these specific generic injectable
products. Additional injectable drugs may also be added to the exclusivity
list subject to agreement by both parties.

Unilife will commence product sales to Hikma in early 2014. Under the terms of
the contract, Unilife will supply Hikma a minimum volume of 175MM units per
year following a rapid high-volume ramp up period.

In addition to product sales, Hikma will pay Unilife $40 million in upfront
and milestone payments. An initial upfront payment of $5 million will be paid
to Unilife immediately, with an additional $15 million in payments expected
during 2014. The final $20 million in milestone-based payments will be paid
the following year.

Market demand for generic injectables is rapidly shifting from vials to
prefilled syringes. However, conventional prefilled devices prevent universal
attachment with any ISO standard needle hub or IV connector and are also
associated with patient safety risks, including spontaneous disconnection and
the leakage or occlusion of medication. The superior design of Unilife's
Unifill Nexus addresses these issues and is expected to rapidly become the
preferred choice to deliver generic injectable drugs.

Mr. Said Darwazah, Chief Executive Officer of Hikma, stated: "This agreement
supports our strategy of developing higher value products and we are extremely
pleased to be partnering with Unilife to develop our generic injectables
capabilities. We look forward to leveraging Unilife's innovative platform of
Unifill syringes to differentiate our injectable products and to increase our
market share."

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated: "Unilife has
developed a full range of innovative and highly differentiated syringes under
our Unifill platform to accommodate the needs of all prefilled biologics,
drugs and vaccines. This strategic partnership with Hikma enables us to
rapidly penetrate the large and fast-growing market for generic injectables.
Hikma is one of the world's fastest growing pharmaceutical companies, and a
top three supplier by volume in the $7 billion U.S. market for generic
injectables. Together with our recently announced long term supply contract
with Sanofi, this partnership with Hikma instantly positions Unilife to become
one of the largest suppliers of prefilled syringes in the world."

The Unifill^® Platform

Unilife has developed an extensive proprietary platform of prefilled syringes
under its Unifill^® brand. Unifill is the world's first and only known
platform of prefilled syringes with automatic and fully integrated needle
retraction. Designed for intuitive use by healthcare workers or
self-injecting patients, an audible, tactile click signals the injection of
the full dose and the automatic activation of the needle retraction mechanism.
Users can control the speed of needle retraction directly from the body into
the syringe barrel by relieving thumb or finger pressure on the plunger to
eliminate the risk of needlestick injuries or the aerosolization (splatter) of
blood or tissue residue. Unifill syringes are compatible with standard
filling and packaging processes, with USP compliant materials in the primary
drug container.

The Unifill Nexus™

The Unifill Nexus is a glass prefilled syringe that can be universally
attached to ISO standard needless luer access devices (NLADs). The Unifill
Nexus is designed to address patient safety concerns relating to the reported
malfunction, breaking or clogging of some conventional glass prefilled
syringes when attached to NLADs. Unlike some other needleless prefilled
syringes, it features an ISO standard luer lock tip that is designed for
universal attachment onto standard needle hubs and IV connectors and prevents
the risk of spontaneous disconnection or leakage of medication. Like other
syringes within the Unifill platform, the Unifill Nexus is compatible with
standard filling and packaging processes and has USP compliant materials in
the primary drug container.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and
commercial supplier of injectable drug delivery systems. Unilife's broad
portfolio includes prefilled syringes with automatic needle retraction, drug
reconstitution delivery systems, auto-injectors, wearable injectors,
intraocular delivery systems and novel devices. Each of these innovative,
differentiated technology platforms can be customized to address specific
customer, drug and patient requirements. Unilife's global headquarters and
state-of-the-art manufacturing facilities are located in York, PA. For more
information, please visit www.unilife.com or download the Unilife IRapp on
your iPhone, iPad or Android device.

About Hikma

Hikma Pharmaceuticals is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and non
branded generic and in-licensed products. Hikma's operations are conducted
through three businesses: "Branded", "Injectable" and "Generics" based
principally in the Middle East and North Africa (MENA) region, where it is a
market leader, the United States and Europe. In 2012, Hikma achieved revenue
of US$1,108.7 million and profit attributable to shareholders of US$100.3

Forward-Looking Statements

Thispress release contains forward-looking statements. All statements that
address operating performance, events or developments that we expect or
anticipate will occur in the future are forward-looking statements.These
forward-looking statements are based on management's beliefs and assumptions
and on information currently available to our management. Our management
believes that these forward-looking statements are reasonable as and when
made. However, you should not place undue reliance on any such forward-looking
statements because such statements speak only as of the date when made. We do
not undertake any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as required by law. In addition, forward-looking statements
are subject to certain risks and uncertainties that could cause actual
results, events and developments to differ materially from our historical
experience and our present expectations or projections. These risks and
uncertainties include, but are not limited to, those described in "Item1A.
Risk Factors" and elsewhere inourAnnual Report on Form 10-Kand those
described from time to time in other reports which we file with the Securities
and Exchange Commission.

General: UNIS-G

Investor / PR Contacts (US):     Analyst Enquiries      Investor Contacts
Todd Fromer / Garth Russell    Lynn Pieper       Jeff Carter
KCSA Strategic                   Westwicke Partners Unilife Corporation
P: + 1 212-682-6300          P: + 1                 P: + 61 2 8346 6500

SOURCE Unilife Corporation

Website: http://www.unilife.com
Press spacebar to pause and continue. Press esc to stop.